197 related articles for article (PubMed ID: 30357394)
21. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Bupathi M; Hays JL; Chen JL
PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
[TBL] [Abstract][Full Text] [Related]
23. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
24. Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.
Mir O; Touati N; Lia M; Litière S; Le Cesne A; Sleijfer S; Blay JY; Leahy M; Young R; Mathijssen RHJ; Van Erp NP; Gelderblom H; Van der Graaf WT; Gronchi A
Clin Cancer Res; 2019 Mar; 25(5):1479-1485. PubMed ID: 30765389
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
27. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
[TBL] [Abstract][Full Text] [Related]
28. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Spigel DR; Burris HA; Greco FA; Shih KC; Gian VG; Lipman AJ; Daniel DB; Waterhouse DM; Finney L; Heymach JV; Hainsworth JD
Cancer; 2018 Jun; 124(11):2355-2364. PubMed ID: 29645086
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Fu S; Hou MM; Naing A; Janku F; Hess K; Zinner R; Subbiah V; Hong D; Wheler J; Piha-Paul S; Tsimberidou A; Karp D; Araujo D; Kee B; Hwu P; Wolff R; Kurzrock R; Meric-Bernstam F
Ann Oncol; 2015 May; 26(5):1012-1018. PubMed ID: 25669829
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
33. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Kurzrock R; Ball DW; Zahurak ML; Nelkin BD; Subbiah V; Ahmed S; O'Connor A; Karunsena E; Parkinson RM; Bishop JA; Ha Y; Sharma R; Gocke CD; Zinner R; Rudek MA; Sherman SI; Azad NS
Clin Cancer Res; 2019 Sep; 25(18):5475-5484. PubMed ID: 31186313
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
[TBL] [Abstract][Full Text] [Related]
35. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
[TBL] [Abstract][Full Text] [Related]
36. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
38. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
39. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
40. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
